Into the Clinic With Nivolumab and Pembrolizumab

In 2015, the US Food and Drug Administration approved the use of nivolumab for treatment of squamous and nonsquamous non-small cell lung cancer (NSCLC) and pembrolizumab for use in patients with NSCLC tumors that express PD-L1. This commentary discusses issues with these two drugs relative to best p...

Descripción completa

Detalles Bibliográficos
Autores principales: Shu, Catherine A., Rizvi, Naiyer A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2016
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4861376/
https://www.ncbi.nlm.nih.gov/pubmed/27026678
http://dx.doi.org/10.1634/theoncologist.2016-0099
_version_ 1782431210990993408
author Shu, Catherine A.
Rizvi, Naiyer A.
author_facet Shu, Catherine A.
Rizvi, Naiyer A.
author_sort Shu, Catherine A.
collection PubMed
description In 2015, the US Food and Drug Administration approved the use of nivolumab for treatment of squamous and nonsquamous non-small cell lung cancer (NSCLC) and pembrolizumab for use in patients with NSCLC tumors that express PD-L1. This commentary discusses issues with these two drugs relative to best practices and target populations.
format Online
Article
Text
id pubmed-4861376
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher AlphaMed Press
record_format MEDLINE/PubMed
spelling pubmed-48613762016-05-16 Into the Clinic With Nivolumab and Pembrolizumab Shu, Catherine A. Rizvi, Naiyer A. Oncologist Commentary In 2015, the US Food and Drug Administration approved the use of nivolumab for treatment of squamous and nonsquamous non-small cell lung cancer (NSCLC) and pembrolizumab for use in patients with NSCLC tumors that express PD-L1. This commentary discusses issues with these two drugs relative to best practices and target populations. AlphaMed Press 2016-05 2016-03-29 /pmc/articles/PMC4861376/ /pubmed/27026678 http://dx.doi.org/10.1634/theoncologist.2016-0099 Text en ©AlphaMed Press
spellingShingle Commentary
Shu, Catherine A.
Rizvi, Naiyer A.
Into the Clinic With Nivolumab and Pembrolizumab
title Into the Clinic With Nivolumab and Pembrolizumab
title_full Into the Clinic With Nivolumab and Pembrolizumab
title_fullStr Into the Clinic With Nivolumab and Pembrolizumab
title_full_unstemmed Into the Clinic With Nivolumab and Pembrolizumab
title_short Into the Clinic With Nivolumab and Pembrolizumab
title_sort into the clinic with nivolumab and pembrolizumab
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4861376/
https://www.ncbi.nlm.nih.gov/pubmed/27026678
http://dx.doi.org/10.1634/theoncologist.2016-0099
work_keys_str_mv AT shucatherinea intotheclinicwithnivolumabandpembrolizumab
AT rizvinaiyera intotheclinicwithnivolumabandpembrolizumab

Ejemplares similares